[Click eStock] "Celltrion, High Profitability of New Drug Jimpenetra → Expected Earnings Growth"

The Third Historical Turning Point for Stock Price Increase Arrives
Jimpentra Sales Expected to Reach 863.6 Billion KRW in 2025
RamsimaSC Sales Expanding Smoothly in Europe

Hana Securities analyzed on the 31st that expectations for performance are rising for Celltrion due to Jimpendra and Remsima SC, and newly issued a 'Buy' investment opinion with a target price of 250,000 KRW. Celltrion closed at 177,300 KRW on the previous trading day.

Jae-kyung Park, a researcher at Hana Securities, said, "Celltrion experienced two stock rallies in 2017 and 2020, and is currently at a turning point for the third stock price increase," adding, "The main catalysts for this stock price rise are Jimpendra and multiple new biosimilars, and a sharp growth in performance is expected by 2025." He added that Jimpendra is expected to show high profitability due to its higher price compared to existing biosimilars, and attention should be paid to Celltrion, which is expected to level up its performance in 2025.

Celltrion set up a booth and presented its new drug Jimpendra at DDW (Digestive Disease Week), the world's largest gastrointestinal disease conference held in Washington D.C., USA, from the 18th to the 21st. Jimpendra is a drug that changes the existing intravenous formulation of infliximab (Remsima) to a subcutaneous injection formulation. It has the advantage of being self-administered and maintaining stable blood concentration.

Additionally, researcher Park said, "The NSP (Net Sales Price) of Jimpendra is about four times that of the existing infliximab, so high profitability can be expected," and "Jimpendra's sales are projected to be 324 billion KRW in 2024 and 863.6 billion KRW in 2025." He also mentioned, "Celltrion is smoothly expanding sales of Remsima SC in Europe."